Taiwan Liposome Company Profit Margin

Taiwan Liposome Company (TLC) currently reports a profit margin of -291.03% as of June 2021. That compares with -1671.25% in the prior-year period — up 82.6% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Taiwan Liposome Company's profit margin history and peer comparisons.

Taiwan Liposome Company's profit margin increased from -1671.25% to -291.03% — a 82.6% year-over-year increase (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Taiwan Liposome Company's profit margin of -291.03% is lower than the Healthcare sector average of 13.89%. That is roughly 2194.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Taiwan Liposome Company's current -291.03% should be judged against Healthcare norms (sector average: 13.89%) and against TLC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -291.03%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Taiwan Liposome Company, and consider following TLC for alerts when major investors trade the stock.